拓扑替康联合化疗治疗晚期宫颈癌的研究综述。
A review of topotecan in combination chemotherapy for advanced cervical cancer.
机构信息
Department of Obstetrics and Gynecology, Main Line Gynecologic Oncology, Lankenau Hospital Wynnewood, PA, USA.
出版信息
Ther Clin Risk Manag. 2008 Feb;4(1):213-8. doi: 10.2147/tcrm.s1771.
Treatment of advanced, recurrent or persistent cervical cancer includes radiotherapy and chemotherapy. Radiation has been the primary treatment modality for locoregionally advanced cervical cancer. Concomitant systemic cisplatin chemotherapy and radiation have shown high response rates with improvements in durable remissions and overall survival. Cisplatin has been the standard medication for the treatment of advanced cervical cancer. Combinations with other chemotherapeutic agents have been the subject of clinical trials with varying results. The toxicity of combination chemotherapy and tolerability of patients are other factors that should be considered in the management of patients with advanced disease. Recently topotecan, in combination with cisplatin, achieved increased response and overall survival rates without further compromising the patients' quality of life. This review focuses on the mechanism of action and toxicities of topotecan, as well as its role as a radio-sensitizer and chemotherapeutic agent in the management of advanced, recurrent, or persistent cervical cancer. Other combination modalities and dosages are also discussed.
治疗晚期、复发性或持续性宫颈癌包括放疗和化疗。放射治疗一直是局部晚期宫颈癌的主要治疗方式。顺铂联合全身化疗和放疗显示出高反应率，持久缓解和总生存率提高。顺铂一直是治疗晚期宫颈癌的标准药物。与其他化疗药物联合应用一直是临床试验的主题，但结果各异。联合化疗的毒性和患者的耐受性是在管理晚期疾病患者时应考虑的其他因素。最近，拓扑替康联合顺铂，在不进一步降低患者生活质量的情况下，提高了反应率和总生存率。本综述重点介绍拓扑替康的作用机制和毒性，以及作为放射增敏剂和化疗药物在治疗晚期、复发性或持续性宫颈癌中的作用。还讨论了其他联合方式和剂量。
Zotero 插件